June 12, 1997New England Journal of Medicine1,902 citationsOpen Access

Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization

TIThe EPILOG InvestigatorsCleveland Clinic

Key Points

Key points are not available for this paper at this time.

Abstract

Inhibition of the platelet glycoprotein IIb/IIIa receptor with abciximab, together with low-dose, weight-adjusted heparin, markedly reduces the risk of acute ischemic complications in patients undergoing percutaneous coronary revascularization, without increasing the risk of hemorrhage.

问 AI

Bookmark

View Full Paper

Cite This Study

The EPILOG Investigators (Thu,) studied this question.

synapsesocial.com/papers/695425a706a3168fc53833e3 https://doi.org/https://doi.org/10.1056/nejm199706123362401

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Standard Versus Low-Dose Weight-Adjusted Heparin in Patients Treated With the Platelet Glycoprotein IIb/IIIa Receptor Antibody Fragment Abciximab (c7E3 Fab) During Percutaneous Coronary Revascularization1997 · 139 citations
2Peripheral vascular complications after conventional and complex percutaneous coronary interventional procedures1992 · 298 citations
3Predictors of late mortality following ablative new-device angioplasty in native coronary arteries1996 · 10 citations
4The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty1992 · 92 citations
5The platelet membrane glycoprotein IIb-IIIa complex1988 · 1,016 citations

问 AI

Bookmark

View Full Paper